Spike S, Recombinant, SARS-CoV-2, aa16-685, Fc Fusion, Avi-tag (SARS-CoV-2)

Cat# 544472-100ug

Size : 100ug

Brand : US Biological



544472 Rabbit Anti-Spike S, Recombinant, SARS-CoV-2, aa16-685, Fc Fusion, Avi-tag (SARS-CoV-2)

Clone Type
Polyclonal
Swiss Prot
P0DTC2
Grade
Purified
Accession #
QHD43416.1
Shipping Temp
Dry Ice
Storage Temp
-70°C

Recombinant protein corresponding to aa16-685 from Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), fused at the C-terminus of the Fc portion of human IgG1, and a C-terminal Avi-tag, expressed in HEK293 cells.||Molecular Weight:|~104kD. This protein runs at a higher MW by SDSPAGE due to glycosylation.||Assay Conditions:|SARS-CoV-2 S1 and ACE2 binding assay was done using ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Kit. SARS-CoV-2 S1 protein and anti-human Fc-HRP were used instead of SARS-CoV-2 Spike protein (RBD) and anti-mouse Fc-HRP respectively.||Applications: |Suitable for use in the study of enzyme kinetics, screening inhibitors and selectivity profiling. Other applications have not been tested. ||Recommended Dilutions:|Optimal dilutions to be determined by the researcher.||Storage and Stability:|Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Source: Recombinant, HEK293 cells|Purity: ≥90% (SDS-PAGE)|Concentration: ~0.5mg/ml|Form: Supplied as a liquid in 8mM Phosphate, pH 8.0, 110mM sodium chloride, 2.2mM KCl, 20% glycerol.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a liquid in 8mM Phosphate, pH 8.0, 110mM sodium chloride, 2.2mM KCl, 20% glycerol.
Purity
≥90% (SDS-PAGE)
References
1. Hoffman, M. et al., Cell. 2020 Apr; 181:1-10. 2. Walls, A. C. et al., Cell. 2020 Mar; 180(2):281-292.